Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection

Journal of Controlled Release

Volumn 52, Issue 3, 1998, Pages 239-252

  Nomura, Takehiko ^a   Saikawa, Akira ^a   Morita, Satoko ^a   Sakaeda, Toshiyuki ^a,c   Yamashita, Fumiyoshi ^a   Honda, Kazuo ^b   Yoshinobu Takakura, ^a   Hashida, Mitsuru ^a  

^a Grad Sch Pharmaceutical Sci   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Intratumoural injection; Macromolecule; Mitomycin C; Pharmacokinetics; Tissue isolated tumour

Indexed keywords

DEXTRAN; DRUG CARRIER; MITOMYCIN C; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; INTRATUMORAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; WALKER CARCINOMA; WHOLE BODY AUTORADIOGRAPHY; WHOLE BODY SCINTISCANNING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA 256, WALKER; DEXTRANS; FEMALE; INJECTIONS, INTRALESIONAL; MITOMYCIN; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; RATS; RATS, WISTAR;

EID: 0032584134     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00185-5     Document Type: Article

References (45)

1. S. Carter, S. Crooke, Mitomycin C: Current Status and New Developments, Academic Press, New York, 1980.
2. Kato T., Nemoto R., Mori H., Takahashi M., Tamakawa Y., Harada M. Chemoembolization with microencapsulated anticancer drugs; An approach to selective cancer chemotherapy with sustained effects. J. Am. Med. Assoc. 245:1981;1123-1127.
3. Hagiwara A., Takahashi T., Lee R., Ueda T. Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particle. Cancer. 59:1987;245-251.
4. Johansson C.J. Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex). Clin. Pharmacokinet. 31:1996;231-240.
5. Melton R.G., Sherwood R.F. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88:1996;153-165.
6. Sahin U., Hartmann F., Senter P., Pohl C., Engert A., Diehl V., Pfreundschuh M. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD3O/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50:1990;6944-6948.
7. Sezaki H., Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Systems. 1:1984;1-38.
8. Takakura Y., Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hemoatol. 18:1995;207-231.
9. Maeda H., Matsumura Y. Tumouritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Systems. 6:1989;193-210.
10. Seymour L.W. Passive tumour targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Systems. 9:1992;135-187.
11. Duncan R., Spreafico F. Polymer conjugates: Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27:1994;290-306.
12. Kojima T., Hashida M., Muranishi S., Sezaki H. Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C. J. Pharm. Pharmacol. 32:1980;30-34.
13. Takakura Y., Kitajima M., Matsumoto S., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumour activities. Int. J. Pharm. 37:1987;135-143.
14. Hashida M., Takakura Y., Matsumoto S., Sasaki H., Kato A., Kojima T., Muranishi S., Sezaki H. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem. Pharm. Bull. 31:1983;2055-2063.
15. Takakura Y., Matsumoto S., Hashida M., Sezaki H. Physicochemical properties and antitumour activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Rel. 10:1989;97-105.
16. Takakura Y., Atsumi R., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. Int. J. Pharm. 37:1987;145-154.
17. Noguchi A., Takahashi T., Yamaguchi T., Kitamura K., Takakura Y., Hashida M., Sezaki H. Tumour localization and in vivo antitumour activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Jpn. J. Cancer Res. 82:1991;219-226.
18. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumour localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300.
19. Noguchi A., Takahashi T., Yamaguchi T., Kitamura K., Takakura Y., Hashida M., Sezaki H. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconjugate Chem. 3:1992;132-137.
20. Takakura Y., Matsumoto S., Hashida M., Sezaki H. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res. 44:1984;2505-2510.
21. Imoto H., Sakamura Y., Ohkouchi K., Atsumi R., Takakura Y., Sezaki H., Hashida M. Disposition characteristics of macromolecules in the perfused tissue-isolated tumour preparation. Cancer Res. 52:1992;4396-4401.
22. Ohkouchi K., Imoto H., Takakura Y., Hashida M., Sezaki H. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumour perfusion system. Cancer Res. 50:1990;1640-1644.
23. Saikawa A., Nomura T., Yamashita F., Takakura Y., Sezaki H., Hashida M. Pharmacokinetic analysis of drug disposition after intratumoural injection in a tissue-isolated tumour perfusion system. Pharm. Res. 13:1996;1436-1442.
24. Nomura T., Nakajima S., Kawabata K., Yamashita F., Takakura Y., Hashida M. Intratumoural pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 57:1997;2681-2686.
25. Schnaar R., Sparks T.F., Roseman S. Cyanogen bromide activation of polysaccharides. Effect of reaction condition on cationic charge and ligand content. Anal. Biochem. 79:1977;513-525.
26. Gullino P.M., Grantham F.H. Studies on the exchange of fluids between host and tumour. I. A method for growing tissue-isolated tumours in laboratory animals. J. Natl. Cancer Inst. 27:1961;679-693.
27. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiol. Dyn. 4:1981;879-885.
28. Song C.W., Levitt S.H. Quantitative study of vascularity in Walker carcinoma 256. Cancer Res. 31:1971;587-589.
29. Barlogie B., Drewinko B. Lethal and cytokinetic effects of mitomycin C on cultured human colon cancer cells. Cancer Res. 40:1980;1973-1980.
30. Kennedy K.A., Rockwell S., Sartorelli A.C. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumour cells. Cancer Res. 40:1980;2356-2360.
31. Jain R.K. Determinants of tumour blood flow: a review. Cancer Res. 48:1988;2641-2658.
32. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gadients in tissue-isolated and subcutaneous tumours: implications for therapy. Cancer Res. 50:1992;4478-4484.
33. Gutmann R., Leunig M., Feyh J., Goetz A.E., Messmer K., Kastenbauer E., Jain R.K. Interstitial hypertention in head and neck tumours in patients: correlation with tumour size. Cancer Res. 52:1993;1993-1995.
34. Jain R.K. Transport of molecules across tumour vasculature. Cancer Metastasis Rev. 6:1987;559-593.
35. Jain R.K. Transport of molecules in the tumour interstitum: a review. Cancer Res. 47:1987;3039-3051.
36. Butler T.P., Grantham F.H., Gullino P.M. Bulk transfer of fluid in the interstitial compartment of mammary tumours. Cancer Res. 35:1975;3084-3088.
37. R.K. Jain, Physiological resistance to the treatment of solid tumours. In: B. Teicher (Ed.), Drug resistance in oncology, New York: Marcel Dekker. (1993).
38. Matsumoto S., Yamamoto A., Takakura Y., Hashida M., Tanigawa N., Sezaki H. Cellular interaction and in vitro antitumour activity of mitomycin C-dextran conjugate. Cancer Res. 46:1986;4463-4468.
39. Masegi M., Wakabayashi N., Sagara K., Teramura Y., Yamamoto A., Takakura Y., Hashida M., Sezaki H. Permeability of macromolecules in cultured endotherial and tumour cell layers on microporous membranes. Int. J. Pharm. (Amst.). 78:1992;103-113.
40. Jain R.K. Delivery of novel therapeutic agents in tumours: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
41. R.K. Jain, Barriers to drug delivery in solid tumours. Scientific American (July), 1994.
42. Sevick E.M., Jain R.K. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res. 48:1988;1201-1207.
43. Gullino P.M., Grantham F.H., Smith S.H., Haggerty A.C. Modifications of the acid-base of the internal milieu of tumours. J. Natl. Cancer Inst. 34:1965;857-869.
44. Honda K., Satomura K., Hashida M., Sezaki H. Topical application of mitomycin C conjugated with dextran (MMC-D): A high molecular weight derivative of mitomycin C. Jpn. J. Cancer Chemother. (Tokyo). 12:1985;311-317.
45. Satomura K., Honda K., Arimoto A., Kikuchi S., Sezaki H., Hashida M. Surgical chemotherapy using mitomycin C-dextran conjugate. Ther. Res. (Tokyo). 2:1985;311-317.